Oncotherapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Oncotherapeutics sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Oncotherapeutics: 17 sponsored US clinical trials, 4 recruiting.
Oncotherapeutics sponsors 17 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 4 trials.
Top-decile sponsor footprint
Oncotherapeutics ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (61.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
NCT06225310
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
NCT06209606
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
NCT03733691
Combination Study for High Risk Multiple Myeloma Patients
NCT03104270
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
NCT02294357
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
NCT02206425
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
NCT02188368
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
NCT01697839
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
NCT01695330
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
NCT01365559
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
NCT01160380
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
NCT01160484
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
NCT00743288
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00316940
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00317811
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
What is open in the Oncotherapeutics pipeline
4 recruiting of 17 indexed (24% open); 8 completed (47%).
Phase mix: 1 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (4 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oncotherapeutics: open-pipeline peers nationwide
Peers matched on 17 registered trials and 24% open enrollment, not the therapeutic-area sidebar.
Oncotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 24% open enrollment (± trial volume)
- HALEON · 24% recruiting · 34 trials
- Scripps Whittier Diabetes Institute · 24% recruiting · 17 trials
- The Mind Research Network · 24% recruiting · 17 trials
- Major Extremity Trauma Research Consortium · 23% recruiting · 30 trials
Related
What to do with this Oncotherapeutics page
17 registered trials is a research-attention snapshot, not an endorsement of Oncotherapeutics or any single study.
- 4 of Oncotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Oncotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Oncotherapeutics pipeline card: 17 registered trials from official public datasets.Report a data error.